Maze Therapeutics, Inc. (MAZE) Balance Sheet
As of 2026-06-30 (10-Q), Maze Therapeutics, Inc. (MAZE) reported total assets of $531.6M, total liabilities of $78.5M and shareholders' equity of $453.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $202.6M. Long-term debt: $39.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MAZEMaze Therapeutics, Inc.Follow MAZE — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|
| Cash and equivalents | 189.2 | 202.6 | |
| Short-term investments | 152.7 | 208.4 | |
| Current assets | 349.7 | 420.4 | |
| Total assets | 397.1 | 531.6 | |
| Current liabilities | 22.6 | 23.0 | |
| Long-term debt | — | 39.0 | |
| Short-term debt | — | 0.0 | |
| Total liabilities | 42.2 | 78.5 | |
| Shareholders' equity | 355.0 | 453.1 |
USD millions · SEC XBRL
Maze Therapeutics, Inc. — questions
- How much cash does Maze Therapeutics, Inc. have?
- $202.6M in cash and cash equivalents as of 2026-06-30.
- How much debt does Maze Therapeutics, Inc. have?
- $39.0M of long-term debt and $0 due within a year as of 2026-06-30.
- What are Maze Therapeutics, Inc.'s total assets?
- $531.6M as of 2026-06-30.
- What is Maze Therapeutics, Inc.'s shareholders' equity?
- $453.1M as of 2026-06-30.
Every figure on this page comes from Maze Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.